Accretion Pharmaceuticals Ltd. (ACCPL-ST) Share Price Within 2% of All-Time High

Accretion Pharmaceuticals Ltd. Share Price stood at Rs 196.75 at 9:31 AM IST, placing the Rs 218.71 crore stock within 2% of its all-time high.

Accretion Pharmaceuticals Ltd. Share Price was at Rs 196.75 at 9:31 AM IST on 12 August 2026, taking the company close to record levels with a market capitalisation of Rs 218.71 crore. The Univest screener identified the stock as trading within 2% of its all-time high, a data-backed event that often draws fresh attention to both valuation and business quality.

For investors tracking Accretion Pharmaceuticals Ltd. Share Price Today, the move matters because a stock approaching its historic peak typically becomes a point of comparison between momentum and fundamentals. In this case, the available data does not establish a company-specific catalyst, but it does confirm that the stock is trading near its ATH and that its valuation and profitability metrics are notable within the Pharmaceuticals & Drugs space.

Accretion Pharmaceuticals Ltd. Share Price also sits in a part of the market where relative metrics can shape sentiment quickly. The company’s P/E stands at 22.62, P/B at 4.19, ROE at 27.18 and ROCE at 12.62. Those numbers place the stock in an interesting position against its industry benchmark and listed peers. Univest data further shows that the company belongs to the Healthcare sector and Pharmaceuticals & Drugs industry, making sector-level comparison especially relevant while the stock trades within striking distance of its historic peak.

Accretion Pharmaceuticals Ltd. Share Price Today: Within 2% of All-Time High

Accretion Pharmaceuticals Ltd. Share Price Today was Rs 196.75 when the Univest screener qualified the event at 9:31:33 AM IST on 12 August 2026. That exact level is also the event qualification price, confirming that the stock was screened in real time as trading within 2% of its all-time high. The reference event is proximity to a historic peak, not confirmation of a new record, and that distinction matters for how investors read the move.

When a stock like Accretion Pharmaceuticals Ltd. Share Price trades near its ATH, market participants typically begin weighing whether the current level reflects stronger earnings quality, a rerating in valuation, or simply a renewed focus on the company within its sector. The supplied data confirms the price event, but it does not establish a company-specific trigger behind the move.

At a market capitalisation of Rs 218.71 crore, Accretion Pharmaceuticals Ltd. Share Price is being watched in the small-cap segment of the Healthcare universe, where sentiment can often be influenced by comparative valuation and profitability readings. Its current valuation multiples and return ratios therefore become more important when the stock is close to record levels.

That is why the near-ATH setup is relevant: investors are not just observing price strength, but also asking whether the underlying numbers justify the attention. From here, the next step is to examine the company’s fundamentals and place Accretion Pharmaceuticals Ltd. Share Price in the context of its industry and peer group.

Accretion Pharmaceuticals Ltd. (ACCPL-ST) Share Price Today: Price Action Analysis

Metric	Value
LTP at 2% Qualification	Rs 196.75
Market Capitalisation	Rs 218.71 crore
All-Time High Position	Trading within 2% of its all-time high

Accretion Pharmaceuticals Ltd. (ACCPL-ST) traded at Rs 196.75. Reported volume was 0.

Accretion Pharmaceuticals Ltd. (ACCPL-ST) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 218.71 crore
P/E Ratio	22.62x
P/B Ratio	4.19x
ROE	27.18%
ROCE	12.62%
EPS	Rs 8.7
Book Value Per Share	Rs 46.91
Dividend Yield	0%

Accretion Pharmaceuticals Ltd. was valued at a P/E ratio of 22.62x, a P/B ratio of 4.19x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 27.18% and ROCE of 12.62%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 8.7, book value per share of Rs 46.91, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Accretion Pharmaceuticals Ltd. Share Price reflects a market capitalisation of Rs 218.71 crore, which indicates company size rather than quality by itself. To understand whether the current interest has a numerical basis, the main reported markers are valuation and profitability. The stock is trading at a P/E of 22.62 and a P/B of 4.19. These are meaningful because they show how the market values the company’s earnings and accounting net worth while the stock trades close to record levels.

Profitability data adds more texture. Return on equity stands at 27.18, which signals that the company is generating a relatively strong return on shareholder capital based on the supplied numbers. Return on capital employed is 12.62, a more moderate reading that still helps frame operating efficiency from a broader capital base. Looked at together, ROE and ROCE suggest that investors tracking Accretion Pharmaceuticals Ltd. Share Price are likely focusing on return ratios, not just headline price movement.

The reported EPS is Rs 8.7. EPS matters because it represents earnings attributable to each share and helps explain why the stock commands a P/E of 22.62. Book value per share is Rs 46.91, showing the accounting net worth behind each share; against the current price of Rs 196.75, that translates into the stated P/B multiple of 4.19. Dividend yield is 0, which indicates that the current or historical payout is not contributing to the investment case in the supplied dataset.

Overall, the available fundamentals do add context to investor interest. Accretion Pharmaceuticals Ltd. Share Price is not only near its ATH; it is also trading with a combination of above-benchmark profitability and a valuation profile that deserves close comparison with the broader Pharmaceuticals & Drugs universe. That makes ownership and sector positioning the next logical lens, although sector evidence is the stronger verified dataset here.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	22.62x
Benchmark Median P/E	18.58x
Benchmark Average P/E	60.93x
Benchmark P/E Range	0x to 3,374.81x
Company P/B Ratio	4.19x
Benchmark Median P/B	1.78x
Company ROE	27.18%
Benchmark Median ROE	9.93%
Company ROCE	12.62%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 218.71 crore
Benchmark Median Market Cap	Rs 145.18 crore

Accretion Pharmaceuticals Ltd. (ACCPL-ST) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a P/E ratio of 22.62x, which is above the benchmark median of 18.58x, a difference of +21.74%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a ROE of 27.18%, which is above the benchmark median of 9.93%, a difference of +173.72%. Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a ROCE of 12.62%, which is below the benchmark median of 12.97%, a difference of -2.7%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Accretion Pharmaceuticals Ltd. Share Price sits within the Healthcare sector and the Pharmaceuticals & Drugs industry. Univest benchmark data for the same industry covers 135 companies, while the broader Healthcare sector count stands at 195. That benchmark scope matters because it allows investors to compare the company against a large listed sample rather than a narrow handpicked group.

On valuation, the company’s P/E of 22.62 is above the same-industry median of 18.58, while remaining far below the industry average of 60.93. The benchmark range is wide, running from 0 to 3374.81, which suggests dispersion in profitability and valuation across the industry. The company’s P/E is 21.74% above the median, so Accretion Pharmaceuticals Ltd. Share Price is trading at a premium to the typical industry stock on earnings, though not at the upper extreme of the sector range.

The P/B picture is firmer. The company’s P/B of 4.19 compares with an industry median of 1.78 and average of 2.42, against a range from -16.74 to 16.32. That places the stock 135.39% above the median on this measure. Profitability, however, partly offsets that richer multiple. ROE of 27.18 is well above the industry median of 9.93 and average of 7.89, or 173.72% above the median. ROCE of 12.62 is slightly below the median of 12.97 and below the average of 15.54, which translates into -2.7% versus median.

In size terms, Accretion Pharmaceuticals Ltd. Share Price represents a market capitalisation of Rs 218.71 crore, above the industry median of Rs 145.18 crore but below the average of Rs 486.28 crore. The benchmark market-cap range spans Rs 6.31 crore to Rs 2,949.87 crore. That places the company in the lower-middle part of a wide industry spectrum, making relative execution and valuation particularly important for investors following the stock on Univest.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Accretion Nutraveda Ltd.	ANL	216.48	42.71	6.86	106.65	21.4
Gennex Laboratories Ltd.	GENNE	215.98	10.3	0.97	10.71	13.24
Sanjivani Paranteral Ltd.	SANJIVIN	230.88	34.04	4.79	0	266.43
Coral Laboratories Ltd.	CORALAB	204.46	12.48	0.98	10.74	13.35
BIO MEDICA LABORATORIES L	BMLL-SM	184.22	15.79	10.16	13.67	10.17

Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a P/E ratio of 22.62x compared with the displayed peer median of 15.79x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 27.18% compares with a peer median of 10.74% across the companies shown in the table. ROCE stood at 12.62% versus the displayed peer median of 13.35%, providing a capital-efficiency comparison. Accretion Pharmaceuticals Ltd. (ACCPL-ST) has a market capitalisation of Rs 218.71 crore. Among the 5 peers shown, 1 have a larger market capitalisation.

Peer data gives a more direct read on how Accretion Pharmaceuticals Ltd. Share Price compares with similarly sized listed names in Pharmaceuticals & Drugs. The company’s market capitalisation of Rs 218.71 crore is close to Accretion Nutraveda Ltd. at Rs 216.48 crore and Gennex Laboratories Ltd. at Rs 215.98 crore, slightly below Sanjivani Paranteral Ltd. at Rs 230.88 crore, above Coral Laboratories Ltd. at Rs 204.46 crore and above BIO MEDICA LABORATORIES L at Rs 184.22 crore. That makes the peer set useful because the size band is broadly comparable.

On valuation, Accretion Pharmaceuticals Ltd. trades at 22.62 times earnings. That is lower than Accretion Nutraveda at 42.71 and Sanjivani Paranteral at 34.04, but higher than Gennex at 10.3, Coral at 12.48 and BIO MEDICA at 15.79. Its P/B of 4.19 is lower than Accretion Nutraveda’s 6.86 and BIO MEDICA’s 10.16, but higher than Gennex at 0.97, Coral at 0.98 and slightly below Sanjivani Paranteral at 4.79.

Profitability is mixed but respectable in this context. Accretion Pharmaceuticals Ltd. reports ROE of 27.18, which is well above Gennex at 10.71, Coral at 10.74 and BIO MEDICA at 13.67, but below Accretion Nutraveda’s 106.65. It is also above Sanjivani Paranteral, which shows 0 on ROE. On ROCE, the company’s 12.62 is close to Gennex at 13.24 and Coral at 13.35, above BIO MEDICA at 10.17, below Accretion Nutraveda at 21.4 and far below Sanjivani Paranteral at 266.43. For investors watching Accretion Pharmaceuticals Ltd. Share Price, the peer picture suggests a stock that is neither the cheapest nor the most expensive, but one with stronger ROE than several direct comparables.

Why Investors Are Watching Accretion Pharmaceuticals Ltd.

Accretion Pharmaceuticals Ltd. Share Price is being watched because the stock has entered a zone that often sharpens market attention. Near-ATH setups matter when they coincide with distinctive valuation and profitability readings, and that is the case here. Univest data shows the stock at Rs 196.75 and within 2% of its all-time high, while the company also reports a P/E of 22.62, P/B of 4.19, ROE of 27.18 and ROCE of 12.62. In short, investors are looking at both price positioning and relative fundamentals.

• Accretion Pharmaceuticals Ltd. Share Price qualified on the Univest screener at Rs 196.75 on 12 August 2026 at 9:31:33 AM IST.
• The company’s market capitalisation stands at Rs 218.71 crore in the Healthcare sector.
• P/E of 22.62 is above the same-industry median of 18.58, while P/B of 4.19 is above the median of 1.78.
• ROE of 27.18 is stronger than the industry median of 9.93, while ROCE of 12.62 is slightly below the median of 12.97.
• Peer comparisons place the stock around the middle of its comparable valuation range, with stronger ROE than several peers.

What investors may monitor next is whether Accretion Pharmaceuticals Ltd. Share Price continues to hold attention through relative fundamentals rather than price proximity alone. Sector benchmarks, peer multiples and return ratios are the key verified markers in the current dataset. On Univest, those comparisons make the near-all-time-high event more relevant than a simple price snapshot.

About Accretion Pharmaceuticals Ltd.

Accretion Pharmaceuticals Ltd. operates in the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. Based on the verified dataset, that places the company in a segment where investors typically compare businesses through earnings multiples, book-value multiples and return ratios rather than through price action alone.

For readers searching Accretion Pharmaceuticals Ltd. Stock News or Accretion Pharmaceuticals Ltd. Share Price analysis, the key company context is its position inside a broad listed pharmaceuticals universe. Univest industry benchmarks cover 135 companies in the same industry and 195 companies in the wider Healthcare sector. That gives useful context for understanding how the company is being valued by the market and how its profitability compares with sector medians and averages.

At a market capitalisation of Rs 218.71 crore, Accretion Pharmaceuticals Ltd. is part of the smaller listed end of the pharmaceutical market, though it remains above the industry median market cap of Rs 145.18 crore. This matters because smaller healthcare names are often assessed through relative valuation discipline and return efficiency. In the current dataset, Accretion Pharmaceuticals Ltd. Share Price attracts attention not only because it is near its ATH, but also because the company’s ROE, ROCE, P/E and P/B provide enough measurable context for a deeper comparison within its industry group.

Track Accretion Pharmaceuticals Ltd. Share Price on Univest

Use Accretion Pharmaceuticals Ltd. (ACCPL-ST) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Accretion Pharmaceuticals Ltd. Share Price can use Univest to track live market moves alongside deeper stock analysis. On the platform, users can monitor share price action, valuation ratios such as P/E and P/B, profitability markers like ROE and ROCE, market capitalisation trends, 52-week levels and broader market insights. Univest also helps place company data against peer and sector benchmarks, which is especially useful when a stock is trading near its all-time high. For investors researching Accretion Pharmaceuticals Ltd. Share Price Today, that combination of live tracking and comparative context can make the event easier to interpret in a disciplined way.

Frequently Asked Questions

What is Accretion Pharmaceuticals Ltd. Share Price Today?

Ans. Accretion Pharmaceuticals Ltd. Share Price Today was Rs 196.75 when the Univest screener qualified the event at 9:31:33 AM IST on 12 August 2026. At that level, the stock was identified as trading within 2% of its all-time high.

Why is Accretion Pharmaceuticals Ltd. Share Price in focus?

Ans. Accretion Pharmaceuticals Ltd. Share Price is in focus because Univest identified the stock within 2% of its all-time high. The company also carries a market capitalisation of Rs 218.71 crore, keeping valuation and profitability metrics under closer watch.

What is the market capitalisation of Accretion Pharmaceuticals Ltd.?

Ans. Accretion Pharmaceuticals Ltd. has a market capitalisation of Rs 218.71 crore. That places it above the same-industry median market cap of Rs 145.18 crore, though below the industry average of Rs 486.28 crore in Univest benchmark data.

What are the key valuation ratios for Accretion Pharmaceuticals Ltd.?

Ans. Accretion Pharmaceuticals Ltd. is trading at a P/E of 22.62 and a P/B of 4.19. Those readings are above the same-industry medians of 18.58 for P/E and 1.78 for P/B, according to Univest benchmark figures.

How profitable is Accretion Pharmaceuticals Ltd. based on reported ratios?

Ans. The company reports ROE of 27.18 and ROCE of 12.62. ROE is well above the same-industry median of 9.93, while ROCE is slightly below the industry median of 12.97, showing mixed but notable profitability signals.

What do EPS, book value and dividend yield show for Accretion Pharmaceuticals Ltd.?

Ans. Accretion Pharmaceuticals Ltd. reports EPS of Rs 8.7, book value per share of Rs 46.91 and dividend yield of 0. EPS reflects earnings per share, book value shows net worth per share, and yield indicates no current payout contribution.

How does Accretion Pharmaceuticals Ltd. compare with industry peers?

Ans. Accretion Pharmaceuticals Ltd. trades at a P/E of 22.62, lower than Accretion Nutraveda at 42.71 and Sanjivani Paranteral at 34.04, but higher than Gennex, Coral Laboratories and BIO MEDICA on the supplied peer comparison data.

Which sector and industry does Accretion Pharmaceuticals Ltd. belong to?

Ans. Accretion Pharmaceuticals Ltd. belongs to the Healthcare sector and Pharmaceuticals & Drugs industry. Univest benchmark coverage spans 135 same-industry companies and 195 same-sector companies, giving investors a broad comparative context for the stock.